Heart Metabolics

Pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”).

placeLondon, England, United Kingdom calendar_todayFounded 2013 groups4 employees language heartmetabolics.com

Registered entities

Investor mix

12 investors on record; lead investors include AshHill, ttcf.com.au, VenBio, Seroba Life Sciences.

Investor typeCountShare
Venture capital433%
Bank & private debt18%
Other / undisclosed758%
Coming soon